BG
AXSM icon

Bellevue Group’s Axsome Therapeutics AXSM Stock Holding History

Bellevue Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$538K Sell
3,181
-24,419
-88% -$4.22M 0.01% 113
2025
Q4 		$5.04M Sell
27,600
-24,735
-47% -$3.45M 0.1% 75
2025
Q3 		$6.36M Sell
52,335
-3,918
-7% -$441K 0.13% 69
2025
Q2 		$5.87M Sell
56,253
-40,154
-42% -$4.25M 0.13% 78
2025
Q1 		$11.2M Sell
96,407
-22,523
-19% -$2.57M 0.25% 71
2024
Q4 		$10.1M Sell
118,930
-248,251
-68% -$22.8M 0.19% 80
2024
Q3 		$33M Sell
367,181
-149,352
-29% -$13M 0.53% 57
2024
Q2 		$41.6M Sell
516,533
-168,943
-25% -$12.5M 0.68% 37
2024
Q1 		$54.7M Buy
685,476
+50,104
+8% +$4.21M 0.83% 32
2023
Q4 		$50.6M Buy
635,372
+3,885
+0.6% +$260K 0.77% 42
2023
Q3 		$44.1M Buy
631,487
+57,124
+10% +$4.27M 0.71% 42
2023
Q2 		$41.3M Buy
574,363
+133,013
+30% +$9.81M 0.59% 56
2023
Q1 		$27.2M Buy
441,350
+4,692
+1% +$308K 0.4% 67
2022
Q4 		$33.7M Sell
436,658
-59,866
-12% -$3.58M 0.45% 64
2022
Q3 		$22.2M Sell
496,524
-320,617
-39% -$16M 0.32% 78
2022
Q2 		$31.3M Buy
817,141
+97,659
+14% +$3.09M 0.44% 64
2022
Q1 		$29.8M Buy
719,482
+67,545
+10% +$2.09M 0.35% 82
2021
Q4 		$24.6M Sell
651,937
-101,008
-13% -$3.72M 0.25% 97
2021
Q3 		$24.8M Buy
752,945
+400,924
+114% +$15.6M 0.25% 98
2021
Q2 		$23.7M Buy
+352,021
New +$21.1M 0.23% 102

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group's AXSM Position: Q1 2026 in Review

Bellevue Group reduced its Axsome Therapeutics (AXSM) stake by 88% in Q1 2026, selling an estimated $4.22M and leaving 3,181 shares worth $538K. The position accounts for 0.01% of the portfolio, ranked #113.

Bellevue Group first reported a position in AXSM in Q2 2021 and has held it in 20 quarters since. The position peaked at $54.7M in Q1 2024. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Bellevue Group held 3,181 shares of Axsome Therapeutics worth $538K as of Q1 2026.
  • Bellevue Group sold 24,419 Axsome Therapeutics shares in Q1 2026, an estimated $4.22M.
  • Axsome Therapeutics made up 0.01% of Bellevue Group's portfolio in Q1 2026, its #113 holding.
  • Bellevue Group first reported a position in Axsome Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Bellevue Group's Axsome Therapeutics position peaked at $54.7M in Q1 2024.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.